Regulatory MSD secures EC approval for Enflonsia to prevent infant RSV infection Pharmaceutical Business ReviewThis approval authorises Enflonsia's marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway.RegulatoryInfectious DiseaseRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. RegulatoryInfectious DiseaseRead full story Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
